

*duplicate*

Claim 1. (Previously Amended) A method of preparing a medicament for treating oedema comprising admixing a chain of 7 to 17 contiguous amino acids derived from the region of human TNF- $\alpha$  from Ser<sup>100</sup> to Glu<sup>116</sup> or from the region of mouse TNF- $\alpha$  from Ser<sup>99</sup> to Glu<sup>115</sup> with a pharmaceutically acceptable carrier.

Claims 2-9. (Cancelled)

*duplicate*

Claim 10. (Previously Amended) A pharmaceutical composition for treating oedema comprising a chain of 7 to 17 contiguous amino acids derived from the region of human TNF- $\alpha$  from Ser<sup>100</sup> to Glu<sup>116</sup> or from the region of mouse TNF- $\alpha$  from Ser<sup>99</sup> to Glu<sup>115</sup> and a pharmaceutically acceptable carrier.

Claims 11-18. (Cancelled)

---

*C1*

Claim 19. (Currently Amended) A method of treating oedema comprising administering a composition of ~~claim 10~~ to a person in need of said treatment, said composition being pharmaceutical composition for treating oedema comprising a peptide chain of 7 to 17 contiguous amino acids derived from the region of human TNF- $\alpha$  from Ser<sup>100</sup> to Glu<sup>116</sup> or from the region of mouse TNF- $\alpha$  from Ser<sup>99</sup> to Glu<sup>115</sup> and a pharmaceutically acceptable carrier.

C1  
Claim 20. (Currently Amended) A method of inducing oedema resorption comprising administering a composition of ~~claims 10~~ to a person suffering from oedema, said composition being pharmaceutical composition for treating oedema comprising a peptide chain of 7 to 17 contiguous amino acids derived from the region of human TNF- $\alpha$  from Ser<sup>100</sup> to Glu<sup>116</sup> or from the region of mouse TNF- $\alpha$  from Ser<sup>99</sup> to Glu<sup>115</sup> and a pharmaceutically acceptable carrier.

---

Claim 21. (new) A method of claim 19 or 20, wherein said peptide comprises a chain of 11 to 16 contiguous amino acids.

Claim 22. (new) A method of claim 19 or 20, wherein said peptide comprises a chain of 13 to 15 contiguous amino acids.

C2  
Claim 23. (new) A method of claim 19 or 20, wherein said peptide comprises a chain of 14 contiguous amino acids.

Claim 24. (new) A method of claim 23, wherein said chain of 14 contiguous amino acids are chosen from the group consisting of the contiguous amino acid sequences

QRETPEGAEAKPWY (SEQ ID NO:1) and PKDTPEGAEELKPWY (SEQ ID NO:2).

Claim 25. (new) A method of claim 19 or 20, wherein said peptide is circularized.

Claim 26. (new) A method of claim 25, wherein said peptide is circularized by replacing the NH<sub>2</sub>- and COOH-terminal amino acids by cysteine so that a disulfide bridge is formed between the latter cysteines.

C2 Claim 27. (new) A method of claim 26, wherein said circularized peptides are chosen from the group consisting of the circularized peptides CGQRETPEGAEAKPWYC (SEQ ID NO:4) and CGPKDTPEGAELKPWYC (SEQ ID NO:5).

Claim 28. (new) A method of claim 19 or 20, wherein said oedema is pulmonary oedema.

---